Grupo farmacéutico · Estados Unidos
KING
Un grupo de 7 empresas con 30 medicamentos en 2 países.
Estructura del grupo
7 empresas en 2 países
Cargando…
Grupo farmacéutico · Estados Unidos
Un grupo de 7 empresas con 30 medicamentos en 2 países.
7 empresas en 2 países
Una cuenta gratuita para las apps de Prognia: Ward para estudiar, Osler para respuestas clínicas con sus fuentes y la red para encontrar a tus colegas.
Prognia forma los grupos a partir de los nombres que publican las autoridades reguladoras y de los vínculos entre empresas; no son una estructura societaria oficial.
Todos los medicamentos de todas las empresas del grupo, primero los vigentes.
1–25 de 30
| Medicamento | Principio activo | País | Estado | Autorización |
|---|---|---|---|---|
| ALTACE1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG **Federal Register · Tablet | Ramipril | Estados Unidos | No comercializado | 2007 |
| ALTACE1.25mg | 10mg | 2.5mg | 5mg · Capsule | Ramipril | Estados Unidos | No comercializado | 1991 |
| APOGEN10mg base/ml | 40mg base/ml · Injectable | Gentamicin | Estados Unidos | No comercializado | |
| AVINZA120mg | 30mg | 45mg | 60mg | 75mg | 90mg · Capsule, extended release | Morphine | Estados Unidos | No comercializado | 2002 |
| BICILLIN C-R150,000 units/ml; 150,000 units/ml | 300,000 units/ml; 300,000 units/ml · Injectable | Benzathine benzylpenicillin, Penicillin procaine | Estados Unidos | Comercializado | 1953 |
| BICILLIN C-R 900/300900,000 units/2ml; 300,000 units/2ml · Injectable | Benzathine benzylpenicillin, Penicillin procaine | Estados Unidos | Comercializado | 1953 |
| BICILLIN L-A300,000 units/ml | 600,000 units/ml · Injectable | Benzathine benzylpenicillin | Estados Unidos | Comercializado | 1952 |
| CORZIDE5MG; 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG; 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Bendroflumethiazide, Nadolol | Estados Unidos | No comercializado | 1983 |
| CROMOPTIC4% · Solution/drops | Cromolyn | Estados Unidos | No comercializado | 1999 |
| CYTOMEL0.005mg base | 0.025mg base | 0.05mg base · Tablet | Liothyronine sodium | Estados Unidos | Comercializado | 1956 |
| HUMATIN250mg base · Capsule | Paromomycin | Estados Unidos | No comercializado | 1969 |
| INTAL0.8mg/inh · Aerosol, metered | Cromolyn | Estados Unidos | No comercializado | 1985 |
| INTAL10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Cromolyn | Estados Unidos | No comercializado | 1982 |
| KLEBCIL1gm base/3ml | 500mg base/2ml | 75mg base/2ml · Injectable | Kanamycin | Estados Unidos | No comercializado | |
| LEVOXYL0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0 · Tablet | Levothyroxine | Estados Unidos | Comercializado | 2001 |
| LORABID100mg/5ml | 200mg/5ml · For suspension | Loracarbef | Estados Unidos | No comercializado | 1991 |
| LORABID200mg | 400mg · Capsule | Loracarbef | Estados Unidos | No comercializado | 1991 |
| MAXOLON10mg base · Tablet | Metoclopramide | Estados Unidos | No comercializado | |
| PROCANBID1gm | 500mg · Tablet, extended release | Procainamide | Estados Unidos | No comercializado | 1996 |
| SILVADENE1% · Cream | Silver sulfadiazine | Estados Unidos | Comercializado | 1973 |
| SKELAXIN400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Metaxalone | Estados Unidos | No comercializado | 1962 |
| SYNERCID500mg · Injectable | Quinupristin, Dalfopristin | Estados Unidos | Comercializado | 1999 |
| SYNERCID350mg/vial; 150mg/vial | 420mg/vial; 180mg/vial · Injectable | Dalfopristin, Quinupristin | Estados Unidos | No comercializado | 1999 |
| TAPAZOLE10MG | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Thiamazole | Estados Unidos | No comercializado | 1950 |
| TIGAN300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Trimethobenzamide | Estados Unidos | No comercializado | 1974 |
Dónde es titular o fabricante de medicamentos, y cuántos están vigentes.
| País | Medicamentos | Vigentes | Anteriores | Empresas |
|---|---|---|---|---|
| Estados Unidos | 27 | 27 | 0 | EmpresasTodos los medicamentos |
| Canadá | 3 | 0 | 3 | EmpresasTodos los medicamentos |
También en los registros de Brasil, Malasia, Reino Unido
Los grupos ATC a los que pertenecen la mayoría de sus medicamentos, de mayor a menor.
Los principios activos presentes en la mayoría de sus medicamentos.
Cómo lo escriben los registros, normalizado: sin forma jurídica, tildes ni mayúsculas.
Recopilado por Prognia a partir de los registros públicos de medicamentos y empresas que aparecen abajo. No se usan logotipos.
Prognia forma los grupos a partir de los nombres que publican las autoridades reguladoras y de los vínculos entre empresas; no son una estructura societaria oficial.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licencia: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licencia: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licencia: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licencia: Open Government Licence Canada
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licencia: Open Government Licence v3.0; Crown copyright MHRA factual register
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licencia: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
Informa de un error o solicita la retiradaLas correcciones de la propia empresa son bienvenidas.
Mantenga correctos los medicamentos de KING en Prognia, vea cómo los consultan los profesionales y responda a lo que preguntan. Una llamada de 20 minutos, en inglés.
Reservar una llamadaGrupos farmacéuticos conocidos, cada uno con todas sus empresas.
Ordenados por su número de medicamentos.